Threshold Announces Clinical Update on Evofosfamide in Relapsed/Refractory Multiple Myeloma to Be Presented at ASCO 2015
- Stocks gear up for Big Tech earnings; yen toys with danger zone
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises on robust EU data as Mideast tensions linger
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
Threshold Pharma (THLD) Reports Data on Evofosfamide in Relapsed/Refractory Multiple Myeloma to Be Presented at ASCO
May 13, 2015 5:08 PM EDTThreshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that new clinical data from its ongoing Phase 2 clinical trial evaluating evofosfamide (previously known as TH-302), an investigational compound, with bortezomib (Velcade) and dexamethasone in patients with relapsed/refractory multiple myeloma will be presented on Sunday, May 31, 2015, at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place May 29 - June 2, 2015, in Chicago, Illinois (Abstract #8579). In addition, a trials-in-progress poster will be presented on the Company's Phase 2 trial of evofosfamide in patients with advanced melanoma (Abstract #TPS9089). Abstracts are now available on... More